Results 211 to 220 of about 49,423 (253)
Some of the next articles are maybe not open access.
Dermatologic Therapy, 2022
Bimatoprost is a synthetic prostaglandin structural analogue used among other indications to increase eyelash growth. The aim of this prospective, open‐label study was to evaluate the safety and efficacy of topical bimatoprost in the treatment of eyelash
J. Ricar +3 more
semanticscholar +1 more source
Bimatoprost is a synthetic prostaglandin structural analogue used among other indications to increase eyelash growth. The aim of this prospective, open‐label study was to evaluate the safety and efficacy of topical bimatoprost in the treatment of eyelash
J. Ricar +3 more
semanticscholar +1 more source
Myasthenia gravis with alopecia totalis
Pediatrics International, 2007Myasthenia gravis was diagnosed on the basis of a positive Tensilon test in a 4-year-old male child with alopecia totalis. His scalp hair and eyebrows had began to disappear at the age of 10 months. No other physical abnormalities such as motor paralysis, were seen except for left ptosis and alopecia totalis.
Kensuke Harada +3 more
openaire +3 more sources
Dermatologic Therapy, 2022
Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by intense itching and recurrent eczematous lesions. 1 Systemic treatments such as dupilumab, Janus kinase (JAK) inhibitors, and immunosuppressive agents are considered ...
T. Seo +4 more
semanticscholar +1 more source
Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by intense itching and recurrent eczematous lesions. 1 Systemic treatments such as dupilumab, Janus kinase (JAK) inhibitors, and immunosuppressive agents are considered ...
T. Seo +4 more
semanticscholar +1 more source
Review of treatment for alopecia totalis and alopecia universalis
International Journal of Dermatology, 2017AbstractAlopecia areata (AA) is an autoimmune disease directed at the hair follicle. Although usually limited to patchy hair loss over the scalp (focalis), AA can present as total loss of scalp hair (totalis; AT) or as total loss of both scalp and body hair (universalis; AU).
Sama Kassira +3 more
openaire +3 more sources
Pediatric dermatology, 2022
Alopecia totalis (AT) is a cosmetically debilitating chronic disease characterized by non‐scarring hair loss of the entire scalp. The clinical course of AT is highly unpredictable, and effective durable treatment options are limited.
Ariane L'Ecuyer +3 more
semanticscholar +1 more source
Alopecia totalis (AT) is a cosmetically debilitating chronic disease characterized by non‐scarring hair loss of the entire scalp. The clinical course of AT is highly unpredictable, and effective durable treatment options are limited.
Ariane L'Ecuyer +3 more
semanticscholar +1 more source
Journal of Cosmetic Dermatology, 2022
report where the efficacy of low- dose tofacitinib was not inferior to that of a higher- dosage regimen, while the higher dose did not induce additional hair growth in patients who responded to 5 mg daily tofacitinib.
K. Sardana, S. Mathachan, P. Gupta
semanticscholar +1 more source
report where the efficacy of low- dose tofacitinib was not inferior to that of a higher- dosage regimen, while the higher dose did not induce additional hair growth in patients who responded to 5 mg daily tofacitinib.
K. Sardana, S. Mathachan, P. Gupta
semanticscholar +1 more source
Alopecia Totalis and Topical Mustine
Archives of Dermatology, 1993To the Editor.— Seven patients with long-standing alopecia totalis (duration >5 years) had not responded to therapies including topical steroids, intralesional steroids, and topical dinitrochlorobenzine plus diphencyprone. Because of a lymphocytic effect of nitrogen mustard 1 and the involvement of lymphocytes in the pathogenesis of alopecia areata, 2
M. Jovanovic, J. Latona, P. V. Harrison
openaire +3 more sources
Archives of Dermatology, 1963
Regrowth of hair in patients with alopecia areata and alopecia totalis has been demonstrated following intralesional injection or systemic administration with corticosteroid drugs.1-4Intralesional injection is painful and may be followed by atrophy, and systemic administration is often accompanied by the undesirable effects of these drugs.
Kenneth A. Gill, Donald L. Baxter
openaire +3 more sources
Regrowth of hair in patients with alopecia areata and alopecia totalis has been demonstrated following intralesional injection or systemic administration with corticosteroid drugs.1-4Intralesional injection is painful and may be followed by atrophy, and systemic administration is often accompanied by the undesirable effects of these drugs.
Kenneth A. Gill, Donald L. Baxter
openaire +3 more sources
Dermatology, 2021
Background: Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. Although there is an increased understanding of AA pathogenesis and progress in its treatments, the outcome of AA patients ...
Tao Zhang, Yingli Nie
semanticscholar +1 more source
Background: Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. Although there is an increased understanding of AA pathogenesis and progress in its treatments, the outcome of AA patients ...
Tao Zhang, Yingli Nie
semanticscholar +1 more source
JAMA: The Journal of the American Medical Association, 1974
ABSTRACT To the Editor.— In my opinion, the dosages that Dr. Orentreich recommended for alopecia (229:204, 1974) are inadequate and would result in the unsuccessful treatment of many patients who could benefit from an increased dosage of both preparations.
openaire +3 more sources
ABSTRACT To the Editor.— In my opinion, the dosages that Dr. Orentreich recommended for alopecia (229:204, 1974) are inadequate and would result in the unsuccessful treatment of many patients who could benefit from an increased dosage of both preparations.
openaire +3 more sources